---
title: "Labelling change allows removal of aspirin following HeartMate 3 implant"
date: "2024-08-21T13:59:32.000Z"
publishedDate: "21 août 2024"
summary: "Abbott has announced that the US Food and Drug Administration (FDA) has approved a change to its label for its HeartMate 3 left ventricular assist device (LVAD) allowing the removal of aspirin from its post-implantation medication regime. The labelling update has also been approved by regulatory agencies in Canada and the European Union."
importance: ""
sourceUrl: "https://cardiovascularnews.com/heartmate-3-aspirin-labelling/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-08-21-labelling-change-allows-removal-of-aspirin-following-heartmate-3-implant"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/11/St_Jude_Medical_HeartMate3_main.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/heartmate-3-aspirin-labelling/"
---

![Labelling change allows removal of aspirin following HeartMate 3 implant](https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/11/St_Jude_Medical_HeartMate3_main.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/heartmate-3-aspirin-labelling/*

## L’essentiel

Abbott has announced that the US Food and Drug Administration (FDA) has approved a change to its label for its HeartMate 3 left ventricular assist device (LVAD) allowing the removal of aspirin from its post-implantation medication regime. The labelling update has also been approved by regulatory agencies in Canada and the European Union.

## Lien source

https://cardiovascularnews.com/heartmate-3-aspirin-labelling/
